Key result
Dampening adrenergic signaling may mitigate atherosclerosis and aneurysm progression by modulating neuroimmune crosstalk.
Neurovascular crosstalk, particularly sympathetic innervation, plays a significant role in atherosclerosis and aneurysm progression, presenting a potential target for disease-modifying interventions.
PURPOSE OF REVIEW: Peripheral nerves are increasingly recognized as regulators of vascular pathology, shaping arterial tone, inflammation, and structural remodeling. This review delineates how neural circuits interface with the aortic wall, considers sympathetic and sensory pathways in atherosclerosis and aneurysm pathophysiology, and discusses emerging experimental approaches and therapeutic strategies. RECENT FINDINGS: Autonomic and sensory neural circuits are increasingly recognized as modulators of arterial disease. In experimental atherosclerosis, neuroimmune crosstalk shapes vascular inflammation and influences plaque stability. Limited available evidence from human and experimental studies suggest increased sympathetic innervation within aneurysm tissue. In preclinical models, aneurysm remodeling was linked with sympathetic input, and interventions that reduce noradrenergic signaling via sympathetic denervation or pharmacological adrenergic blockade attenuated disease severity. Improved understanding of the role for innervation in vascular pathophysiology may open therapeutic opportunities, including neuromodulation and pharmacological interventions. Clarifying sources of heterogeneity between models and clinical data can potentially refine therapeutic targets and patient selection, and advance opportunities for precision interventions. Peripheral neural circuits are integral to vascular homeostasis in health and disease, interfacing with blood vessels and regulating their physiology. Converging human and preclinical evidence implicates sympathetic innervation in disease development, and that dampening adrenergic signaling via denervation or adrenergic blockade may mitigate disease progression. This review discusses mechanistic neuroimmune crosstalk across atherosclerosis and aneurysm biology and outlines some potential translational opportunities. Together, the advances position neurovascular crosstalk as a potentially tractable axis for disease-modifying interventions.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) conducted a review in Atherosclerosis and aneurysm. Sympathetic denervation or pharmacological adrenergic blockade was evaluated. Dampening adrenergic signaling via sympathetic denervation or pharmacological blockade may mitigate atherosclerosis and aneurysm progression by modulating neuroimmune crosstalk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: